BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 545 filers reported holding BIO-TECHNE CORP in Q1 2024. The put-call ratio across all filers is 1.05 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,257,601 | +1.8% | 17,552 | 0.0% | 0.66% | -1.2% |
Q1 2024 | $1,235,485 | -13.8% | 17,552 | 0.0% | 0.67% | -23.9% |
Q2 2023 | $1,432,770 | -2.6% | 17,552 | -1.1% | 0.88% | -17.5% |
Q4 2022 | $1,471,286 | +16.8% | 17,752 | +297.8% | 1.06% | +7.3% |
Q3 2022 | $1,260,000 | -18.6% | 4,463 | 0.0% | 0.99% | -13.4% |
Q2 2022 | $1,547,000 | -33.3% | 4,463 | -0.5% | 1.14% | -17.1% |
Q4 2021 | $2,320,000 | +5.2% | 4,485 | -1.4% | 1.38% | -4.4% |
Q3 2021 | $2,205,000 | +7.6% | 4,550 | 0.0% | 1.44% | +7.5% |
Q2 2021 | $2,049,000 | +16.6% | 4,550 | -1.1% | 1.34% | +8.9% |
Q1 2021 | $1,757,000 | +47.8% | 4,600 | -4.2% | 1.23% | +29.4% |
Q3 2020 | $1,189,000 | +30.7% | 4,800 | 0.0% | 0.95% | +0.6% |
Q1 2020 | $910,000 | -13.7% | 4,800 | 0.0% | 0.94% | +4.0% |
Q4 2019 | $1,054,000 | +12.2% | 4,800 | 0.0% | 0.91% | +4.8% |
Q3 2019 | $939,000 | – | 4,800 | – | 0.87% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
Westwind Capital | 27,946 | $9,687,000 | 3.17% |
MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |